On October 15, 2015, FDA is conducting a public meeting on Patient-Focused Drug Development for Nontuberculous Mycobacterial Lung Infections. FDA is interested in obtaining patients’ perspectives on the impact of Nontuberculous Mycobacterial Lung Infections on daily life and patient views on treatment approaches.

In the afternoon, FDA will hold a workshop and provide information for and gain perspective from patients and patient advocacy organizations, health care providers, academic experts, and industry on various aspects of clinical development of drug products intended to treat NTM lung infections.

To register : http://www.fda.gov/Drugs/NewsEvents/ucm453877.htm